WILEX AG plans reduction of share capital


Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)

PDF Download

Munich, Germany, 10 April 2014. WILEX AG will publish its invitation to the annual general meeting, which will be held on 23 May, 2014, in the Federal Gazette on Monday, 14 April 2014. The agenda will include a draft resolution of the Executive Management and Supervisory Board on an ordinary reduction of WILEX AG share capital by EUR 23,456,628.00 to EUR 7,818,876.00 by consolidation of the issued no par value shares in a ratio of 4:1 from 31,275,504 to 7,818,876 shares, pursuant to §§ 222 ff. of the German Stock Corporation Act. To obtain an even ratio, three shares will be surrendered free of charge by one shareholder prior to the reduction and will be collected by the Company.

The reason for this measure is that for several months the price of WILEX AG’s shares was repeatedly below their nominal value. By consolidating four no par value shares to one share the price of the WILEX share will be significantly increased above the nominal value of one Euro. This gives greater flexibility and transaction capacity to WILEX AG in respect of the minimum issue price according to § 9, par. 1 of the German Stock Corporation Act. No specific capital measures are currently planned, but due to the financial and structural situation of the Company this accounting measure is seen as urgently necessary. Being an accounting measure, the reduction will result in a transfer from subscribed capital to capital reserves on the equity and liabilities side of the balance sheet of WILEX AG. This measure does not affect the value of the company.

The invitation to the annual general meeting of WILEX AG will be available on 14 April, 2014 on the Company’s website under http://www.wilex.de/press-investors/annual-general-meeting/agm2014/.

+++ End of Ad hoc release +++

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available at www.wilex.com

Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 10, 81675 Munich, Germany 
For press enquiries
MC Services AG
Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-126
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 389 | Heute: 2